CA-THALES
6.10.2021 07:02:05 CEST | Business Wire | Press release
Thales and Google Cloud today announced a strategic agreement to co-develop a sovereign hyperscale cloud offering for France. Operated by a joint company with Thales as the majority shareholder, it will meet the criteria of the French ‘Trusted Cloud.’ With this new offering, French companies and public sector organizations will benefit from all the power, security, flexibility, agility and sovereignty offered by the respective technologies of the two organizations.
By addressing the highest legal and technical requirements for ‘Trusted Cloud’, the Thales and Google Cloud offering will enable private and public sector organisations who need to meet the criteria - defined by France’s Information Systems Security Agency (ANSSI)2 - to benefit from cloud computing services, in accordance with the country’s sovereign cloud strategy.
The joint offer of Thales and Google Cloud is based on the most advanced technologies and services of each partner. Google Cloud’s services, which will be enhanced and complemented with new innovations regularly, will bring elasticity, agility and technological openness, enabling companies to innovate transparently and autonomously, without vendor lock-in.
Thales, a leader in cybersecurity for more than 40 years, will bring the necessary guarantees of France’s sovereignty requirements by ensuring the management of encryption keys, access, identities, and cyber threat monitoring with its Cybersecurity Operations Center. Thales thus provides the levels of trust and of security required from French customers so that they can migrate their most sensitive applications to the cloud while maintaining control.
French companies and public sector institutions will be able to benefit from a set of hyperscale cloud services that are:
- operated by a dedicated, newly formed company under French law, held in majority by Thales;
- hosted in France, within infrastructure that is separate from Google Cloud, with a separate network and servers controlled and operated by the new company;
- supported locally by the new company, ensuring customer service is handled in France;
- locally secured with identity management, data encryption, administration and supervision being provided by the new company;
- regularly enhanced via rolling software updates that are evaluated and validated within a security sandbox managed by Thales; and
- managed on a sustainably developed infrastructure.
"To adapt to the diversity of our customers’ cloud needs, Thales offers a wide range of options with partners in its ecosystem. Thanks to this unique collaboration with Google Cloud, we will be able to help power the digital transformation for organizations of all sizes and industries that want to keep control and sovereignty over their data and that of their customers. Together, we will address the criteria defined by the government for a trusted cloud, as well as environmental goals with a sustainable approach for the infrastructure we will build,” said Marc Darmon, Executive Vice President, Secure Communications and Information Systems at Thales.
“Thales and Google Cloud have a joint vision to deliver the most innovative and trusted solutions to companies and public sector organizations in France. Our unique approach to addressing the concerns of French citizens and government bodies, including the development of a new company, ensures organizations can benefit from the innovation and agility of the cloud, without compromising on the security, privacy and sovereignty required by the French government,” said Thomas Kurian, CEO at Google Cloud.
“The government's national cloud strategy clearly specifies the state's willingness to use and promote high-performance and trusted cloud offerings. The challenge is to have the widest possible range of solutions compliant with the SecNumCloud repository which details the technical, operational and legal security rules capable of effectively protecting data and processes hosted in a cloud service. ANSSI therefore enthusiastically welcomes this ambitious project that meets these criteria," said Guillaume Poupard, Director General of the National Information Systems Security Agency (ANSSI.)
About Google Cloud
Google Cloud accelerates organizations' ability to digitally transform their business with the best infrastructure, platform, industry solutions and expertise. We deliver enterprise-grade solutions that leverage Google's cutting-edge technology – all on the cleanest cloud in the industry. Customers in more than 200 countries and territories turn to Google Cloud as their trusted partner to enable growth and solve their most critical business problems.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
1
“Hyperscale” refers to cloud computing based on an optimized computing architecture in terms of storage, power, energy consumption and scalability.
2
The Trusted Cloud label will offer a double level of security – both legal and technical – and will allow French companies and administrations to benefit from the best cloud services. Some of the world’s most efficient cloud services are published by non-European companies: these services will also be eligible for the label under certain conditions, notably concerning the entity operating these services and the location of the data. (source: https://www.numerique.gouv.fr/uploads/Strategie-nationale-pour-le-cloud.pdf
)
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005894/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
